Proteins > Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C
Page last updated: 2024-08-07 17:06:53
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C
A dual specificity calcium/calmodulin-dependent 3,5-cyclic nucleotide phosphodiesterase 1C that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q14123]
Synonyms
Cam-PDE 1C;
3',5'-cyclic-AMP phosphodiesterase;
3.1.4.-;
3',5'-cyclic-GMP phosphodiesterase;
3.1.4.35;
Hcam3
Research
Bioassay Publications (29)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 7 (24.14) | 18.7374 |
| 1990's | 8 (27.59) | 18.2507 |
| 2000's | 7 (24.14) | 29.6817 |
| 2010's | 4 (13.79) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
Compounds (37)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| my 5445 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| my 5445 | Homo sapiens (human) | Ki | 9.5000 | 1 | 1 |
| theophylline | Homo sapiens (human) | IC50 | 320.0000 | 1 | 1 |
| cilostamide | Homo sapiens (human) | Ki | 22.0000 | 1 | 1 |
| cilostazol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| dipyridamole | Homo sapiens (human) | IC50 | 72.5000 | 2 | 2 |
| etazolate | Homo sapiens (human) | Ki | 60.0000 | 1 | 1 |
| amrinone | Homo sapiens (human) | IC50 | 1,000.0000 | 5 | 5 |
| 1-methyl-3-isobutylxanthine | Homo sapiens (human) | IC50 | 3.4000 | 1 | 1 |
| milrinone | Homo sapiens (human) | IC50 | 306.8571 | 7 | 7 |
| nifedipine | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| nimodipine | Homo sapiens (human) | IC50 | 1.2430 | 1 | 1 |
| nitrendipine | Homo sapiens (human) | IC50 | 1.8500 | 1 | 1 |
| papaverine | Homo sapiens (human) | IC50 | 15.3000 | 2 | 2 |
| 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | Homo sapiens (human) | IC50 | 250.0000 | 1 | 1 |
| rolipram | Homo sapiens (human) | IC50 | 133.3333 | 3 | 3 |
| rolipram | Homo sapiens (human) | Ki | 200.0000 | 1 | 1 |
| sulmazole | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| eg 626 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| enoximone | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| imazodan | Homo sapiens (human) | IC50 | 1,200.4857 | 7 | 7 |
| bufrolin | Homo sapiens (human) | IC50 | 16.0000 | 1 | 1 |
| tadalafil | Homo sapiens (human) | IC50 | 10.0000 | 3 | 3 |
| 9-(2-hydroxy-3-nonyl)adenine | Homo sapiens (human) | Ki | 200.0000 | 1 | 1 |
| 9-(2-hydroxy-3-nonyl)adenine | Homo sapiens (human) | IC50 | 16.0000 | 1 | 1 |
| cilomilast | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| vinpocetine | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| vinpocetine | Homo sapiens (human) | Ki | 14.0000 | 1 | 1 |
| 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone | Homo sapiens (human) | IC50 | 1,400.0000 | 6 | 6 |
| idoxifene | Homo sapiens (human) | IC50 | 1.5000 | 1 | 1 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| t 1032 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| pf 04217903 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| an2728 | Homo sapiens (human) | IC50 | 71,000.0000 | 1 | 1 |
| sildenafil | Homo sapiens (human) | IC50 | 0.7398 | 6 | 6 |
| zaprinast | Homo sapiens (human) | IC50 | 13.0750 | 4 | 4 |
| vardenafil | Homo sapiens (human) | IC50 | 0.2650 | 2 | 2 |
| Imidazosagatriazinone | Homo sapiens (human) | IC50 | 0.7900 | 1 | 1 |
| 6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2h-pyran-4-yl)-1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidin-4-one | Homo sapiens (human) | IC50 | 1.3940 | 1 | 1 |
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| rolipram | Homo sapiens (human) | IC25 | 1,400.0000 | 1 | 2 |
| pf-2545920 | Homo sapiens (human) | Activity | 0.0021 | 1 | 1 |
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.Journal of medicinal chemistry, , Nov-26, Volume: 36, Issue:24, 1993
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.Journal of medicinal chemistry, , Nov-26, Volume: 36, Issue:24, 1993
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlJournal of medicinal chemistry, , Volume: 30, Issue:11, 1987
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cardiotonic agents. 1-Methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3 (2H)-isoquinolinones and related compounds. Synthesis and activity.Journal of medicinal chemistry, , Volume: 32, Issue:2, 1989
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Cardiotonic agents. 5. 1,2-Dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-6-methyl-2-oxo-3- pyridinecarbonitriles and related compounds. Synthesis and inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:6, 1987
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlJournal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.Journal of medicinal chemistry, , Nov-26, Volume: 36, Issue:24, 1993
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.Journal of medicinal chemistry, , Mar-25, Volume: 42, Issue:6, 1999
Aryl sulfonamides as selective PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Oct-06, Volume: 8, Issue:19, 1998
9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.Journal of medicinal chemistry, , Jun-06, Volume: 40, Issue:12, 1997
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.Journal of medicinal chemistry, , Jul-05, Volume: 39, Issue:14, 1996
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for tJournal of medicinal chemistry, , Volume: 32, Issue:2, 1989
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlJournal of medicinal chemistry, , Volume: 30, Issue:11, 1987
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.Journal of medicinal chemistry, , Volume: 27, Issue:9, 1984
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.Journal of medicinal chemistry, , 05-23, Volume: 62, Issue:10, 2019
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Volume: 60, 2013
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.Bioorganic & medicinal chemistry letters, , May-02, Volume: 15, Issue:9, 2005
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlJournal of medicinal chemistry, , Volume: 30, Issue:11, 1987
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.Journal of medicinal chemistry, , Volume: 30, Issue:11, 1987
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.Journal of medicinal chemistry, , Volume: 27, Issue:9, 1984
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.Journal of medicinal chemistry, , 05-23, Volume: 62, Issue:10, 2019
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Volume: 60, 2013
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.Journal of medicinal chemistry, , May-19, Volume: 48, Issue:10, 2005
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.Bioorganic & medicinal chemistry letters, , May-02, Volume: 15, Issue:9, 2005
Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 15, Issue:17, 2005
1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.Bioorganic & medicinal chemistry letters, , Jul-21, Volume: 13, Issue:14, 2003
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.Journal of medicinal chemistry, , May-19, Volume: 48, Issue:10, 2005
Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine.Journal of medicinal chemistry, , Feb-18, Volume: 37, Issue:4, 1994
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.Journal of medicinal chemistry, , Nov-26, Volume: 36, Issue:24, 1993
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.Journal of medicinal chemistry, , Volume: 28, Issue:5, 1985
Enables
This protein enables 6 target(s):
| Target | Category | Definition |
|---|
| 3',5'-cyclic-AMP phosphodiesterase activity | molecular function | Catalysis of the reaction: 3',5'-cyclic AMP + H2O = AMP + H+. [GOC:ai, RHEA:25277] |
| calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activity | molecular function | Catalysis of the reactions: 3',5'-cyclic AMP + H2O = AMP + H+ and 3',5'-cyclic GMP + H2O = GMP + H+; this activity is activated by binding to calcium-bound calmodulin. [PMID:8557689, PMID:9419816] |
| calmodulin binding | molecular function | Binding to calmodulin, a calcium-binding protein with many roles, both in the calcium-bound and calcium-free states. [GOC:krc] |
| metal ion binding | molecular function | Binding to a metal ion. [GOC:ai] |
| 3',5'-cyclic-GMP phosphodiesterase activity | molecular function | Catalysis of the reaction: 3',5'-cyclic GMP + H2O = GMP + H+. [RHEA:16957] |
| calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity | molecular function | Catalysis of the reactions: nucleoside 3',5'-cyclic GMP + H2O = GMP + H+; this activity is activated by binding to calcium-bound calmodulin. [GOC:jid] |
Located In
This protein is located in 2 target(s):
| Target | Category | Definition |
|---|
| lysosome | cellular component | A small lytic vacuole that has cell cycle-independent morphology found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions. [GOC:mah, ISBN:0198506732] |
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| neuronal cell body | cellular component | The portion of a neuron that includes the nucleus, but excludes cell projections such as axons and dendrites. [GOC:go_curators] |
Involved In
This protein is involved in 1 target(s):
| Target | Category | Definition |
|---|
| cAMP-mediated signaling | biological process | An intracellular signaling cassette that starts with production of cyclic AMP (cAMP), and ends with activation of downstream effectors that further transmit the signal within the cell. [GOC:signaling] |